We actively communicate on our business, services and technical capabilities. Use the resources on this page to browse through recent news, to subscribe to our news services or to meet us at one of our forthcoming events.
22 Dec 2021 - We are happy to share the latest scientific publication from the PolyPeptide Innovation Team, Dr. Renan Revetti Duran, Innovation Scientist and Dr. Olivier Ludemann-Hombourger, Global Director, […]
Read more1 Dec 2021 - PolyPeptide Group AG, a global leader in peptide development and manufacturing, today announced the appointment of Neil Thompson as Director Global Sales and Marketing and member […]
Read more10 Nov 2021 - PolyPeptide Group AG (“PolyPeptide”) has been informed that Draupnir Holding B.V. (“Draupnir”), which held 60.0% of PolyPeptide’s share capital as of close of trading on SIX […]
Read more1 Sep 2021 - Long-term collaborative development process for peptide API successfully completed and continued with commercial supply agreement PolyPeptide is pleased to announce that its customer Cara Therapeutics (Nasdaq: […]
Read more17 Aug 2021 - PolyPeptide Group AG (SIX: PPGN), a global leader in peptide custom development and manufacturing, today announced its results for the first half of 2021: – Revenue […]
Read more25 Jun 2021 - PolyPeptide Group AG, a global leader in peptide development and manufacturing, today announced the appointment of Christina Del Vecchio as General Counsel and member of the […]
Read more11 May 2021 - The city of Torrance, California, honored Jane Salik for her investment in the Torrance community and her outstanding contributions to the Science and Peptide Industry. 05-11-21 […]
Read more5 May 2021 - PolyPeptide Group AG ("PolyPeptide" or "the Group"), a global leader in peptide development and manufacturing, today announced that the Joint Global Coordinators have exercised in full the over-allotment option granted in connection with its Initial Public Offering (the "IPO") at the offer price of CHF 64 per share.
Read more29 Apr 2021 - Today the PolyPeptide Group became a public company. Our shares are being traded on SIX, the Swiss Stock Exchange. What an exhilarating day! Today the PolyPeptide […]
Read more